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HER4 PROMOTES A STEM-LIKE PHENOTYPE IN OSTEOSARCOMA
Rocio Krystal Rivera-Valentin, B.S.
Advisory Professor: Eugenie S. Kleinerman, MD

Metastatic disease to the lungs is the primary cause of death for patients with
pediatric osteosarcoma (OS). OS has a high degree of heterogeneity and genomic
instability, making understanding the pathogenesis and drivers of metastasis of this
disease challenging. In an effort to explain tumoral heterogeneity, the tumor initiating
cell model (TIC) states that tumors are composed of cells that form the majority of
the tumor and are terminally differentiated. This model however, attributes
tumorigenesis, metastasis and chemoresistance to a distinct cell population with a
stem-like phenotype that can be identified using selective markers. OS appears to
follow this model where OS cells with tumor initiating potential can be identified by
expression of Stro1, CD117 and embryonic stem cell transcription factors such as
Sox2, Nanog and Oct3/4. Additionally, OS stem-like cells display high aldehyde
dehydrogenase activity and sarcosphere formation under limited nutrient media and
anchorage independence. These markers are not feasible targets for therapy due to
their expression on normal tissue stem cells; however, upstream regulators of this
phenotype may be targetable. Therefore, we investigated other modulators of the
stem-like phenotype.
Her4, a transmembrane receptor of the EGFR family, has been recently
studied for its role in cancer. Previously, we demonstrated that Her4 is highly
expressed in neuroblastoma, and OS, while others have shown its importance in
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Ewing sarcoma. This receptor is induced and required to survive stressors, like
anchorage independence, serum starvation and chemotherapy treatment, which are
similar in vitro conditions used to enrich for cells with tumor initiating potential.
Therefore, we hypothesized that Her4 expression is an important regulator of a
stem-like phenotype in OS.
In sarcosphere culture, Her4 expression is induced and precedes the
induction of CD117 and Stro1. OS cells with Her4 deleted by CRISPR/Cas9 have
decreased aldehyde dehydrogenase activity and cannot upregulate the pluripotency
transcription factors Sox2, Oct3/4 and Nanog even when in sarcospheres.
Overexpression of exogenous Her4 was able to cause upregulation of these
transcription factors and increase expression of CD117 in monolayer culture. We
examined Her4 expression in OS diagnostic biopsies and determined the correlation
with metastasis free survival. Tumors with high Her4 expression have higher
probability of developing metastatic disease.
In this dissertation, we demonstrate that Her4 expression is induced by
conditions that enrich stem-like cells and its expression correlates with the ability to
upregulate various OS TIC markers. Therefore, Her4 may contribute to
pathogenesis of OS by conferring a stem-like phenotype.
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Chapter 1: Introduction

1

Osteosarcoma
Osteosarcoma (OS) is the most prevalent bone tumor among pediatric
patients comprising around 60% of all bone tumors in children [1-3]. It affects mostly
adolescents and males more often and earlier than females, but there is an
additional peak incidence amongst patients older than 50, pointing at a possible role
of bone remodeling in tumor initiation common at both ages [1]. Around 4.4 cases
per million per year are diagnosed in the U.S. making this malignancy fairly
uncommon [4]. However, this tumor is highly deadly due to its high metastatic
capacity making OS the second most common cause of cancer related deaths
among pediatric patients [5, 6]. Metastatic disease localizes primarily to the lungs
and less frequently to bone and it is the primary cause of death of OS patients [7].
Patients who initially present with localized disease have a 5-year survival of around
70% compared to patients who present with metastatic disease upon diagnosis who
have less than 20% survival at 5 years [1].
Management of the Osteosarcoma Patient
A common case presentation for OS is a young adolescent who presents with
articular pain and swelling, commonly on the distal femur or proximal tibia, without
any significant history of trauma [8]. Patients who present with OS suspecting
lesions undergo biopsy and imaging studies as part of their initial workup. These
typically include plain radiographs, which can show pathognomonic OS features like
a sunburst pattern indicating bone destruction and deposition and presence of
Codman’s triangle or periosteum elevation around the tumor [1] However, MRI of the
affected area is necessary to determine the extent of disease and neurovascular and
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soft tissue involvement. CT of the lungs is typically used to determine the presence
of metastatic lesions. Histologic evaluation of the tumor is the standard for OS
diagnosis. Lace patterning is indicative and a specific feature of osteosarcoma
indicating osteoid (unmineralized bone matrix) deposition [2].
After the diagnosis of OS has been made, patients are placed on induction
chemotherapy. Besides achieving local tumor control for better surgical excision,
response to induction chemotherapy is the only validated prognostic factor for OS
patients [9]. Patients who present with higher than 90% necrosis after induction are
classified as good responders and have a 5-year disease free survival (DFS) of
around 68%. Poor responders show less than 90% tumor necrosis and 5-year DFS
of 51% [1]. Standard chemotherapy for OS consists of high-dose methotrexate,
doxorubicin (Adriamycin) and cisplatin, also known as MAP therapy. Recent trials
have evaluated whether there is an added benefit of combining ifosfamide and
etoposide with MAP therapy to improve outcome of poor responders but
unfortunately no significant success was obtained, with survival unchanged for over
20 years since the discovery of neoadjuvant chemotherapy and surgical excision [9].
Osteosarcoma Pathogenesis
Unlike other malignancies, no specific recurrent mutations have been
identified as drivers of spontaneous OS, but some genetic alterations predispose to
OS. Patients with mutations in the Retinoblastoma (RB1) gene have an incidence of
osteosarcoma 500 times higher than the normal population and it’s the most
common secondary malignancy these patients present [10-13]. Li-Fraumeni, a
familial syndrome involving germline mutations in p53, confers patients an increased
3

risk in many cancers like breast, brain and osteosarcoma among others [14].
Overall, around 70-80% of OS patients present with some mutation in either of these
genes [1]. Mutations in the RECQL4 (RecQ protein-like 4) gene, which encodes for a
RecQ helicase are associated with Rothmund-Thomson syndrome and have an
increased predisposition to OS [15, 16].
Secondary OS primarily occurs among patients that were treated for another
malignancy during their childhood years. Ionizing radiation and anthracycline or
alkylator containing chemotherapies for the treatment of childhood solid tumors have
been associated with the development of OS in the following two decades after
treatment [5, 17]. Secondary OS also occurs in around 1% of patients with osteitis
deformans or Paget disease of the bone. Although there is a low probability of
malignant transformation among this population, patients who do present secondary
OS have a particular poor outcome [18].
Tumor Heterogeneity in OS
One of the major features of OS is genomic instability [19]. Many studies have
elucidated the complexity of the genomic alterations in this disease by whole
genome sequencing and genome wide association studies (GWAS) on patient
samples compared to paired normal tissue. We have learned from these
investigations that OS is one of the cancers with the highest degree of structural
variation. OS presents with two important phenomena that greatly contribute to
genomic alterations and heterogeneity. Kataegis refers to hypermutated
chromosome regions that have undergone somatic rearrangement [20]. These
regions have been found throughout OS lesions and are not exclusive of specific
4

chromosomes. The second event is chromothrypsis where entire chromosomes are
shattered or broken into small fragments of DNA, which are then reassembled
through non-homologous end joining generating a “stitched up” chromosome with
many translocations and aberrations[20]. These two events make studying and
understanding the biology of OS extremely challenging since there are no specific
recurring chromosomal rearrangements that can be considered driving mutations
among OS patients.
Cancer Stem Cell Model: Understanding tumor heterogeneity
Two models that have been extensively studied in order to understand more
about tumor progression and heterogeneity are the stochastic model and the cancer
stem cell model (CSC). In the early days of cancer biology research, the stochastic
model was widely accepted and many if not all malignancies were thought to follow
its principle [21]. This model posits that all cells within a tumor are biologically
equivalent and have the same tumorigenic potential, therefore tumors are essentially
homogeneous. Heterogeneity then is explained in this model by unpredictable
random alterations in individual cells or particular and unique responses to intrinsic
and extrinsic factors [22]. The stochastic model assumes that it is impossible to
isolate pure populations of cancer cells that do not have tumorigenic potential, since
the microenvironment and other uncontrollable factors will come into play and
generate cells capable of tumor formation [23]. The CSC model is now more widely
accepted over the stochastic model. The CSC model was initially described by Dick
and colleagues in leukemia [22, 24, 25] but since then many malignancies, both
solid and hematologic, have been shown to follow this principle. In the CSC model,
5

tumor heterogeneity is intrinsic. There are broadly two populations within tumors:
those that form the bulk of the tumor and those with tumor initiating potential (see
Figure 1). Cells that form the majority of the tumor have undergone clonal
expansion, are rapidly dividing and can only generate progeny though symmetrical
division [23]. In contrast, there is a small subpopulation of cells that are at the top of
the cellular hierarchy since they can generate, through asymmetrical cell division,
cells at different stages of differentiation. These CSCs or stem-like cells are thought
to resemble normal tissue stem cells in many aspects including self-renewal,
multipotency and differentiation into multiple lineages. This stem-like cell population
is thought to be responsible for chemotherapy resistance and relapse due to their
ability to remain in a quiescent state and their capacity to effectively dispose of
drugs. Markers that identify normal tissue stem cells and also unique markers for
CSCs have been studied in an effort to isolate this population.

6

Figure 1: Hierarchical versus stochastic model to explain tumor heterogeneity.
The hierarchical model (left panel) states that tumor heterogeneity is due to the
coexistence of various cell populations within a tumor. The bulk tumor is composed
of cells that can be effectively targeted by chemotherapy and upon dissociation and
serial transplantation in mice, these cells cannot effectively initiate tumors. A minority
of cells within a tumor has tumor initiating potential and can be identified by markers
used to identify stem cells. These termed stem-like cells can recreate tumors when
serially transplanted and even when very low numbers of cells are injected.
Recurrence and metastatic disease therefore occurs by the inadequate targeting of
this population. On the contrary, the stochastic model (right panel) assumes that
every tumor cell has the same ability to initiate tumors and therefore intrinsic factors
will determine which cell will be clonally expanded in order to achieve tumor survival.

7

Stem-like cells in OS
OS has been shown to follow a CSC model [26-31]. This discovery has paved
the way for further identification of markers capable of selecting populations with
high tumorigenic potential. Various CSC markers and capabilities, both unique to OS
and shared between various malignancies, identify subpopulations of OS cells with
stem-like features and tumor initiating potential. Table 1 summarizes key
characteristics associated with a stem-like phenotype in OS.

Table 1: Validated markers that identify stem-like cells in OS

Markers

CD117 (Mast/stem cell
growth factor receptor)
and Stro1
(mesenchymal stem cell
marker)

Aldehyde
dehydrogenase enzyme

Important Findings
1. Human and murine
OS cells that
expressed these
markers were
highly tumorigenic
in vivo, highly
metastatic and
expressed selfrenewal potential.
2. They also
expressed
additional markers
of stem-like cells
like: CXCR4,
ABCG2 (ABC
transporter for drug
efflux), etc.
3. Displayed sphere
forming ability.
Cells with high
Aldefluor expression

References

[26, 29]

[32]
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(ALDH)

Oct3/4, Sox2 and Nanog

CD133 (Prominin-1)

Membrane dye retention
PKH26 or PKH67

Hoechst-33342 dye
excluding side
population

in OS were
chemoresistant, and
displayed high tumor
initiating frequency.
1. Highly tumorigenic,
sphere forming
and related to
metastasis ability
1. Overexpress
Embryonic stem
cell transcription
factors
2. Invasive and
metastatic
3. Express sphere
forming ability
4. Displayed
multipotency
1. Able to form
spheres under
limited media
2. Form tumors in
vivo under limiting
dilution
3. Display ability to
form spheres under
limiting dilution
4. Chemoresistant

[26, 33, 34]

[27, 31, 35-37]

[38]

[39, 40]

Although OS has been consistently thought of as a malignancy that follows a
tumor initiating cell model, recent studies have suggested that this phenotype can be
inducible demonstrating that tumor cells can have some degree of plasticity allowing
them to adapt to their microenvironment [41]. Similar observations have been made
in melanoma [21], and neural tumors [42-44].
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ErbB4 and EGFR Family
ErbB4 also known as Her4, is a type I transmembrane protein and receptor
tyrosine kinase part of the Epidermal Growth Factor Receptor (EGFR) family. This
family is composed of four members: EGFR, ErbB2, ErbB3 and ErbB4 which share
a similar structural composition consisting of an extracellular domain that contains a
ligand binding site, a transmembrane region and a cytoplasmic domain [45].
Signaling is initiated by ligand binding to the extracellular portion of the receptor,
which triggers receptor activation and homo- or heterodimerization with other family
members. There are ligands that activate multiple family members (betacellulin,
heparin-like binding factor and epiregulin which can bind and activate both EGFR
and Her4) and specific members: EGFR (Epidermal growth factor (EGF),
amphiregulin, TGF-alpha), ErbB3 (Neuregulin 1 and 2) and ErbB4 (Neuregulin 3 and
4)[46, 47]. ErbB2 is an exception in the family because although it does contain an
extracellular domain in its structure, no ligands or specific ligand binding sites have
been identified. Upon activation, the EGFR family undergoes autophosphorylation of
specific tyrosine residues that initiate a myriad of signaling cascades. ErbB3
however possesses very little, if any, kinase activity.
Her4 has an added layer of complexity due to exon splicing events that can
generate various isoforms with specific cellular functions and differentially expressed
within tissues. 4 different juxtamembrane isoforms of this receptor have been
described termed Jma, Jmb, Jmc and Jmd (Figure 2). These isoforms differ by
splicing of exon 16 that codes for a TACE (Tumor necrosis factor-alpha converting
enzyme, also known as ADAM17) binding site rendering the receptor susceptible to

10

cleavage by this enzyme [48-50]. Only isoforms Jma and Jmd contain this exon and
are therefore the cleavable forms of ErbB4 that allow this receptor to undergo a twostep proteolytic processing. After the extracellular fragment of Her4 is released upon
TACE cleavage, the membrane bound receptor of around 100 KD is then the
substrate of a second cleavage event by gamma-secretase. A soluble 80 KD
fragment of Her4 (s80) is released into the cellular cytoplasm where it can affect
many signaling pathways or go into the nucleus to regulate transcription. It is
important to note that s80 Her4 can go into the nucleus due to its nuclear localization
sequence, however this receptor lacks DNA binding domains. Therefore its effects in
regulating transcription are mediated through binding positive and negative
regulators of transcription [48, 50, 51].
Additional cytoplasmic isoforms of ErbB4 exist due to further exon splicing
events. As represented in Figure 2, the CYT1 isoform contains exon 26, which
encodes for a PI3K binding site and can activate both the MAPK and PI3K signaling
pathway; the CYT2 isoform on the contrary does not contain this exon and can only
activate the MAPK pathway upon receptor activation [52, 53].
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Figure 2: Her4 receptor juxtamembrane and cytoplasmic isoforms. The Her4
receptor can be expressed by a combination of various juxtamembrane and
cytoplasmic isoforms that are generated by various splicing events. Expression of
exon 16 allows for expression of a TACE cleavage site, allowing the receptor to
release its extracellular domain and generating a membrane bound fragment that
can be further cleaved by gamma-secretase. This leads to the release of a soluble
80 KDa cytoplasmic fragment that can go to the nucleus and act as a chaperone
affecting transcription. This exon is only expressed in Jma and Jmd isoforms.
Cytoplasmic isoforms differ by the expression of exon 26 of Her4 which codes for a
PI3K binding domain. This exon is contained in the Cyt1 isoform, allowing signaling
through both PI3K and MAPK signaling pathways. The Cyt2 isoform lacks this
domain and can only mediate MAPK signaling.

Her4 in cancer and OS
Early reports on Her4 have been contradictory showing both tumor
suppressor and oncogenic features on the same malignancy. One example of these
incongruent observations has been Her4 expression in breast cancer. Some reports
show that survival is markedly improved in patients that have Her4 positive tumors,
while others point at Her4 as an oncogene with overexpression conferring poor
12

survival [46, 51, 54]. These seemingly disparate results have been explained by
understanding the specific roles of the different Her4 isoforms during
carcinogenesis. Studies comparing cleavable JmaCyt2 versus non-cleavable
JmbCyt2 demonstrated a role in survival for Jma versus a role in cell death for Jmb.
In addition, the cytoplasmic isoforms of the receptor have opposing effects with
CYT1 promoting growth inhibition and CYT2 involved in proliferation. Also, the CYT2
isoform has a greater kinase activity than CYT1 and it is preferentially translocated
to the nucleus [55].
Although Her4 has been mostly studied on breast cancer, other malignancies
have demonstrated the important role this receptor plays in tumorigenesis. Some
examples are in neuroblastoma [56], melanoma [57], Ewing sarcoma [58, 59] and
more recently in lung cancer [60]. Particularly in Ewing sarcoma, reports from Poul
Sorensen’s group showed that Her4 expression mediates chemoresistance and
survival under anchorage independence. In this model, Her4 is upregulated in
response to cell-cell interactions modeled by anchorage independence that activate
E-cadherin and Her4 expression in turn promotes PI3K signaling and survival. In this
malignancy, Her4 expression has also been associated with reduced disease-free
survival. Similar observations were published by our department in neuroblastoma
[56].
Therefore, Her4 expression in various malignancies seems to be important to
promote resistance to chemotherapy, anoikis and promotes development of
metastasis.
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Hypothesis
Because Her4 expression is thought to be necessary for the survival of
tumorigenic cells when they are under various stressors including chemotherapy,
anchorage independence and serum starvation [56, 58] and these conditions are
used to enrich cancer cells with stem-like features, we sought to determine whether
Her4 expression in OS conferred a stem-like phenotype.
We hypothesized that Her4 plays an important role in OS, causing
aggressive and metastatic disease in part by regulating the expression of
stem-like characteristics in OS.

14

Chapter 2: Materials and Methods
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OS cell culture
Human OS cell lines CCHD, CCHK, CCHO, CCHM, Maos, HOS, MG63,
SJSA, U2OS, SaOS2 were maintained in high-glucose Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen, Carlsbad , CA) supplemented with 10% fetal bovine
serum (FBS, HyClone, Logan ,UT) and 1% penicillin/streptomycin (Gemini BioProducts, Woodland, CA). Cells were incubated at 37°C with 5%CO2 and were kept
in a humidified atmosphere. MG63, SaOS2, Hos, U2OS, SJSA were purchased from
the American Type Culture Collection (ATCC, Manassas, VA). CCHD, CCHO,
CCHM and CCHK are OS cell lines obtained from patients at the Children’s Cancer
Hospital at the University of Texas MD Anderson Cancer Center. Maos was derived
from a patient at the University of Michigan. CCHD was obtained from a
pretreatment biopsy of a proximal femoral lesion in an 18-year-old male with
pulmonary metastases upon diagnosis. CCHO was obtained from a hip lesion of a
22-year-old male who presented T5 spinal metastasis. Unfortunately, additional
information regarding the origin of remaining patient derived cell lines (CCHM,
CCHK and Maos) is not available. Cells were routinely passaged upon reaching
confluency of around 80% using trypsin (TrypLE Express, Invitrogen, Carlsbad, CA).
Sarcosphere Assay
Sarcosphere culture using OS cell lines was performed as previously
described [30] [32] with some modifications . Briefly, 60,000 cells per well of 6-well
poly-Hema (poly 2-hydroxyethyl methacrylate, Sigma, St. Louis, MO) coated plates
were seeded and supplemented with DMEM/F12 (Gibco), B27 supplement (Life
Technologies, Waltham, MA), 50 ng/uL Epidermal Growth factor (EGF, Life
16

Technologies) and 50 ng/uL basic Fibroblastic Growth factor (bFGF, Life
Technologies). Sarcospheres were supplemented EGF and bFGF every other day.
Flow cytometry
To measure the expression of surface markers Stro1, CD117 and Her4, OS
cell lines in monolayer culture were washed with Phosphate Buffered saline (PBS,
Gibco) and detached from culture plates using enzyme-free cell dissociation buffer
(Gibco). Cells were counted using Trypan blue exclusion in a Vi-Cell automated cell
counter (Beckman Coulter). For single cell dissociation, sarcospheres were
collected, washed once in PBS and enzyme-free cell dissociation buffer was added.
Cells were pipetted gently up and down until a uniform cell suspension without
aggregates was observed. Cells were counted manually using a hemacytometer
and trypan-blue (Thermo) exclusion. Cells were suspended in blocking buffer
consisting of PBS, 10% mouse serum (Thermo) and 5mM EDTA (Life Technologies)
and the following antibodies were added: anti-human Stro1 PE or anti-human Stro1
PerCP/Fitc (Santa Cruz Biotechnology, Santa Cruz, CA), anti-human CD117 PeCy7
(eBioscience, San Diego, CA) and anti-human Her4 APC (Novus Biologicals,
Littleton, CO). Samples were stained for 30 minutes in the dark and on ice and were
later washed twice with blocking buffer and either analyzed immediately using the
BD LSRFortessa cell analyzer (BD Biosciences) or fixed in 1% paraformaldehyde
(Electron Microscopy Services) and fixed for later analysis. Analysis was performed
using FlowJo software (Tree Star Inc.).
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Immunofluorescence staining
OS sarcospheres were grown as described for 4 days. At this time,
sarcospheres were collected, washed twice with PBS and incubated in a solution
containing 0.1% Triton (Thermo Scientific) in PBS for 20 minutes at room
temperature to achieve permeabilization. Spheres were washed twice with PBS and
incubated for one hour at room temperature in a protein block solution containing
PBS, 10% goat serum (HyClone) and 0.1% Triton. Following blocking of unspecific
binding, primary antibodies were added at the following dilutions: anti-human Stro1
(Santa Cruz Biotechnology, 1/100); anti-human Her4 (abcam HFR-1, Cambridge,
MA, 1/200); anti-human CD117 (Stem Cell Technologies, Cambrigde, MA, 1/100)
and were left incubating overnight at 4 degrees Celsius. Sarcospheres were washed
three times in PBS and secondary antibodies conjugated to Alexa-Fluor 488 (CD117
or Stro1) or Texas Red (Her4) were added and incubated at room temperature for
1.5 hours in the dark. Cells were washed three times in PBS; one drop of DAPI was
added (Thermo Fischer) and sarcospheres were transferred to slides and visualized
using a Leica Fluorescent microscope.
Western Blot
Whole cell lysates from human OS cell lines were obtained as follows: cells
were detached from culture plates using cell scrapers (Falcon) and washed twice
with cold PBS. Cell pellets were obtained by centrifugation at 13,000 rpm for 5
minutes. These pellets were resuspended in lysis buffer containing: 25mM Tris-HCl
pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 5% Glycerol, phosphatase inhibitor
cocktail (Sigma) and protease inhibitor tablets (Roche Diagnostics). Cell pellets were
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incubated with lysis buffer at 4 degrees Celsius with constant rotation for 30 minutes.
Then, were centrifuged at 13,000 rpm for 10 minutes and supernatant was collected.
Protein concentration was quantified by BCA assay (Thermo Scientific) using
albumin standards to generate a standard curve. Equal lysate concentration
between samples was loaded on 8% SDS-PAGE gels to allow protein separation.
Proteins were transferred to nitrocellulose membranes using the iBlot transfer
system (Invitrogen). Full-length Her4 expression was detected by incubating
nitrocellulose membranes with anti-human Her4 antibody (Abcam) at a dilution of
1/1000 in 5% Bovine serum albumin (BSA, Thermo Scientific) in TBST. Anti-rabbit
secondary antibody conjugated to horseradish peroxidase was used. Pierce ECL
(Thermo Scientific) western blotting substrate was used to detect chemoluminiscent
signal.
Aldefluor Assay
Aldefluor kit (Stem Cell Technologies) was used to measure the activity of
aldehyde dehydrogenase enzyme and the assay protocol provided was followed.
Briefly, after detaching cells from plastic culture dishes, cells were counted and one
million cells were aliquoted in a separate tube. Cells were centrifuged, media was
removed and the remaining cell pellet was resuspended in 1mL of Aldefluor Assay
buffer and placed in a micro centrifuge tube. In a separate micro centrifuge tube 5uL
of the DEAB control were aliquoted. The cell suspension was added 5uL of the
Aldefluor substrate, immediately mixed by pipetting and 500uL of the cell suspension
were added to the DEAB control. Both microcentrifuge tubes were incubated at 37
degrees for 30 minutes, then centrifuged at 1.4 rpm for 5 minutes. Supernatant was
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discarded and the cell pellet was resuspended in 300uL fresh Aldefluor Assay buffer
and analyzed using the BD LSRFortessa.
Real-time Polymerase Chain Reaction (RT-PCR)
To determine the expression of embryonic stem cell transcription factors in
OS cell lines with either Her4 knockout or overexpressing constructs, polymerase
chain reaction (PCR) was used. Total RNA was extracted from OS cell lines using
the RNeasy Mini Kit (Qiagen) and cDNA was prepared through reverse transcription
using the Omniscript Reverse Transcriptase Kit (Qiagen) supplemented with
oligo(dT)s (Invitrogen) and RNAse inhibitor (New England Biolabs) and according to
the instructions provided. Real-time PCR was performed using the Lightcycler 480
(Roche) using relative quantification analysis and the following Taqman probes
(Applied Biosystems): Nanog: Hs04260366_g1; Sox2 : Hs01053049_s1 and Oct4:
Hs04260367_gH. PCR reactions were prepared using Taqman gene expression
master mix (Applied Biosystems) and following the provided protocol.
Statistical Analyses
Triplicate samples were analyzed in each experiment and every experiment
was performed at least three times unless otherwise specified. Statistical analysis
was performed using Student’s t test (GraphPad Software Inc.). Assessment of
survival curves was done with log-rank test. P-values of <0.05 were considered
significant.
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Chapter 3: Her4 is highly expressed and a possible prognostic factor in OS
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Rationale
Previous studies have demonstrated the importance of the Her4 receptor in
mediating an aggressive phenotype in many malignancies [46, 58, 59, 61-64]. More
so, pediatric cancers like Ewing sarcoma and neuroblastoma have increased Her4
expression and this correlates with resistance to chemotherapy and metastatic
disease [58, 59]. Expression of the EGFR family has been reported in OS and
among the family, Her4 is frequently highly expressed in both primary and metastatic
OS lesions [65, 66]. However, no data is available specifically correlating survival
among OS patients that express high Her4 expression in their primary tumors. In
addition, no specific data is available regarding prevalence of the various Her4
isoforms in OS. Therefore, we pursued to understand how Her4 affects survival of
OS patients and specifically which isoforms are differentially expressed in patientderived and commercially available OS cell lines.
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Results
Her4 expression correlates with decreased metastasis free survival
In order to determine correlation between Her4 expression and OS patient
survival we analyzed the Mixed Osteosarcoma Kuijjer database set [67, 68] using
the R2 Genomics Analysis and Visualization platform. This publicly available online
tissue microarray contains gene profiles of 84 primary diagnostic osteosarcoma
biopsies. We generated Kaplan-Meier survival curves with Her4 high (n=40) and low
(n=28) expressing patient biopsies that did not present with metastasis at diagnosis
and that were followed for development of metastasis over a period of 240 months
(20 years). Cutoff for high and low Her4 expression was determined by comparison
with osteoblasts and mesenchymal stem cells used as controls. From the generated
curves we observed that patients with high Her4 expression had a significantly
decreased metastasis free survival that remained steady at 50% after 48 months
(Figure 3). In comparison, patients with low Her4 expression had a significantly
higher metastasis free survival probability of around 90%.
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Figure 3: Metastasis free survival is decreased in OS patients with high Her4
expression. The R2 Genomics Analysis and Visualization platform (Academic
Medical Center; http://r2.amc.nl) was used to create Kaplan-Meier metastasis-free
survival curves using the ‘Mixed Osteosarcoma - Kuijjer - 127 - vst - ilmnhwg6v2’
dataset which comprises genome-wide analysis of 84 high-grade osteosarcoma
diagnostic biopsies. These primary tumors were analyzed for Her4 high and low
expression using osteoblasts (n=3) and mesenchymal stem cells (n=12) as controls.
The R2 generated “scan” cut-off modus was used to determine the threshold point
that most significantly separates high relative gene expression and low relative gene
expression. *p ≤0.05.

Her4 juxtamembrane isoforms are variably expressed in OS cell lines
Next, we wanted to determine the expression of the different juxtamembrane
isoforms of the Her4 receptor in OS. As previously discussed, the complex
processing of this receptor can generate four different juxtamembrane isoforms of
which only two (Jma and Jmd) can undergo a two-step proteolytic cleavage event
releasing a soluble Her4 cytoplasmic fragment. This 80KDa peptide can then
localize to the nucleus to regulate transcription by binding several transcription
factors like STAT5, YAP1 among others [48-50]. We previously showed that Her4 is
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highly expressed and primarily localized to the cytoplasm in patient-derived tumor
biopsies [65, 66]. However, we were lacking information on specific isoform
expression. To have more information regarding the abundance of the
juxtamembrane isoforms of the Her4 receptor, we performed absolute quantification
PCR using primers specifically designed to distinguish between the different
cleavable and non-cleavable isoforms. We noted from this experiment that
compared to established commercially available OS cell lines, 4 out of 5 patientderived OS cell lines have a higher copy number of Her4 overall (Figure 4). In
addition, these cell lines with high Her4 express preferentially the cleavable
juxtamembrane isoform Jma.
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Figure 4: OS cell lines have a variable expression of Her4 with the cleavable
isoform Jma preferentially expressed. Quantitative real-time PCR was performed
using standard curve analysis to determine copy number of the various
juxtamembrane isoforms of the Her4 receptor. Patient derived cell lines CCHD,
CCHO, CCHM and Maos have a higher copy number overall of the Her4 receptor
compared to established OS cell lines MG63, HOS, SJSA, Saos2 and U2OS.
Furthermore, in cell lines that express high Her4 copy number the most prevalent
isoform is Jma, which contains exon 16 and encodes for a TACE cleavage site. This
data suggests that Her4 expression in patient derived cell lines goes in accordance
with Her4 expression in OS patient diagnostic biopsies.

26

Summary
Although reports of Her4 expression in OS showed increased expression of
this receptor in patient biopsies, specific correlation on patient outcome and which
specific isoform is preferentially expressed was lacking. For this purpose, we
performed Kaplan-Meier survival curves using gene array data from primary OS
biopsies and found that Her4 expression correlates with patient outcome indicating
that Her4 may be a prognostic factor. Patients with high Her4 expression had a
higher probability of developing metastasis than those with low expression of this
receptor as shown in Figure 3. This data has translational applicability since current
assessment on prognosis for OS patients is done after 12 weeks of induction
chemotherapy where evaluation of tumor necrosis takes place [1, 9]. However, with
Her4 expression being an important determinant for development of metastatic
disease, patients that present Her4 upon diagnosis can be treated more
aggressively under the expectation that their tumors are likely to metastasize.
Also, we identified the cleavable juxtamembrane isoform Jma to be
preferentially expressed in cell lines derived from patient biopsies compared to
established OS cell lines. This supports a potential role of intracellular Her4 signaling
in OS and is consistent with previously published data showing that Her4 expression
in OS tumors is primarily localized to the cytoplasm.
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Chapter 4: Her4 is induced by sarcosphere culture and leads to up-regulation
of markers that identify OS cells with a stem-like phenotype
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Rationale
Tumor cells able to form distant metastatic lesions need to withstand adverse
environments on the road to metastasis [69, 70]. One important aspect of metastasis
is anoikis, which is described as the ability of cancer cells to grow effectively under
anchorage independence. In vitro, this capacity is studied by growing cancer cells
without allowing them to adhere to plastic surfaces [71]. Under these conditions,
Her4 is upregulated in two pediatric malignancies, Ewing sarcoma and
neuroblastoma. These studies showed that cells that have Her4 expression besides
forming spheroid structures under anchorage independence, are highly
chemoresistant and metastatic compared to those that do not express this receptor
[58, 59].
Furthermore, survival under anchorage independence has become a staple of
cells with tumor initiating potential or stem-like cells [26, 72]. Subpopulations of cells
thought to be stem-like display many distinct attributes including, but not limited to,
growth as spheres under anchorage independence with limited nutrient media,
expression of markers of pluripotency, expression of markers associated with normal
tissue stem cells, high aldehyde dehydrogenase activity and high expression of ABC
transporters leading to high drug clearance and increased chemotherapy resistance
[33, 44, 73-75].
Since Her4 expression in select pediatric malignancies leads to various
attributes that characterize tumor initiating cells in vitro, we wanted to determine
whether Her4 expression in OS correlates with expression of validated makers used
to characterize and isolate OS stem-like cells.
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Results
Sarcosphere culture induces Her4 expression
In Ewing sarcoma cell lines, growth in suspension causes an increase in Ecadherin signaling which ultimately leads to activation of Her4 as a downstream
effector [58]. Similar to these findings, we were able to observe Her4 upregulation in
patient derived OS cell lines after just 4 days in sarcosphere culture, as shown in
Figure 5. For CCHO, Her4 upregulation was observed after 7 days in spheres.
However, unlike previous studies focusing on anchorage independence only, our
sarcosphere culture conditions were more strict and restrictive and included defined
media without fetal bovine serum and supplemented with essential vitamins,
minerals, EGF and FGF (see materials and methods section). These sarcosphere
conditions have been described as stressors that allow selection and enrichment of
cells with tumor initiating capabilities [26, 30]. In addition, in vitro sarcophere
formation is accepted as a more representative model of actual disease in cancer
patients than monolayer culture [71]. Therefore, this data validates a possible
significance of Her4 in stem-like populations in OS. Since OS stem-like cells are
more metastatic and chemoresistant than cells that do not express these traits [26,
29, 30], correlation of Her4 with a stem phenotype in OS provides a feasible
mechanism for our observations of Her4 as a prognostic factor in OS.
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Figure 5: Her4 is inducible by sphere culture. Patient derived cell lines Maos,
CCHD and CCHO were stained with Her4 antibody for flow cytometry analysis both
in monolayer and sphere culture. Maos and CCHD cells show upregulation of Her4
after 4 days under anchorage independence and limited media. CCHO upregulates
Her4 after seven days in these conditions.
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Her4 upregulation in spheres precedes upregulation of stem-like markers
Stro1 and CD117
Subpopulations of cells with Stro1 and CD117 expression in OS have a
higher metastatic potential and can form serially transplanted tumors in very low
numbers recapitulating the initial tumor heterogeneity [29]. Therefore, since these
markers have been specifically studied in OS cells with stem-like phenotype, we
sought to determine whether there was a correlation between Her4 expression and
expression of these markers. For this, we performed flow cytometry staining for Her4
and stemness markers Stro1 and CD117 on various OS cell lines in monolayer
culture and at different time points in sarcosphere. This experiments allowed us to
observe specifically when Her4 upregulation occurs relative to upregulation of these
markers. As Figure 6 shows, Her4 expression is consistently induced early after
cells are placed under sarcosphere conditions but Stro1 expression occurs at later
time points and mostly in cells that are Her4 positive. We also performed
immunofluorescence staining on CCHD sarcospheres and observed that Stro1
expression was limited to cells that co-expressed Her4 (Figure 7).
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Figure 6: Her4 expression in OS sarcospheres is induced prior to expression
of OS stemness marker Stro1. Maos OS cells were placed under sarcosphere
culture and at day 1, 3, 5 and 7 cells were collected, dissociated into single cells,
stained for Her4 and Stro1 and analyzed by flow analysis. In spheres, Her4 is
induced at day 3 of sphere culture but Stro1 expression is not increased until day 7
(top panel). CCHD and CCHO show similar findings at day 4 and day 7, respectively
(bottom panel).
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Figure 7: Stro1 expression co-localizes to Her4 positive cells in sarcospheres.
Immunofluorescence staining was performed for Stro1 and Her4 expression on
CCHD OS cells after 4 days in sarcosphere culture. Her4 expression was
upregulated compared to Stro1. However, Stro1 expression was only found on Her4
positive cells.

After these observations, we decided to analyze the expression of Stro1
specifically gating on Her4 positive and negative cells. Figure 8 shows
representative data for cell line CCHO. As expected, cells with higher expression of
Her4 were also Stro1 positive. Similar results were obtained for CCHD (not shown).
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Figure 8: Her4 positive cells are also Stro1 positive. Representative data for cell
line CCHO is shown. Positive cells for Her4 expression were gated using the isotype
control as a negative Her4 population. Then, histograms were created for both Her4
positive and negative populations showing increased Stro1 expression among Her4
positive cells. Similar findings were observed with CCHD (data not shown).

We also performed similar experiments comparing Her4 to CD117, an
additional marker of stem-like cells in OS, using the CCHO OS cells and observed
similar findings (Figure 9).
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Figure 9: Her4 expression in sarcospheres correlates with CD117 expression.
OS cell line CCHO was analyzed by flow cytometry after staining with Her4 and
CD117 antibodies seven days after seeding under sarcospheres. There is a distinct
population of cells that upregulate both Her4 and CD117 (top panel). Gating on Her4
positive and negative populations in CCHO demonstrates that CD117 positive cells
are also Her4 positive (bottom panel).
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Summary
A variety of surface markers have been identified to effectively characterize
cells with tumor initiating potential in OS (see Table 1). Stro1 expression has been
observed on mesenchymal stem cells and particularly in OS, this marker has been
shown to be preferentially expressed on cells with tumor initiating potential,
generating aggressive tumors in vivo with metastases to the lung [29]. CD117 is also
expressed on stem-like cells in OS and double expression of these markers has
been published to effectively characterize murine OS cells with a stem-like
phenotype, although Stro1 expression is more relevant in human OS cell lines [29].
In this chapter, we have demonstrated that Her4 is upregulated under
sarcosphere culture conditions used to enrich stem-like cells in OS. Different OS cell
lines upregulate Her4 at various time points ranging from 4 to 7 days. One common
finding was that when cells were double stained for Her4 and Stro1 or CD117, cells
that express any of these markers became Her4 positive before expressing them. To
our knowledge, this is the first study to link expression of the Her4 receptor to
markers identifying stem-like populations.
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Chapter 5: Genomic deletion of Her4 using CRISPR/Cas9 negatively impacts
expression of stemness markers in OS
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Rationale
To understand the specific contributions of the Her4 receptor in OS we
designed CRISPR (Clustered Regularly Interspaced Palindromic Repeats) /Cas9
constructs targeting this receptor. The CRISPR/Cas9 system was discovered in
bacteria and has been successfully implemented in molecular biology due to its
convenience and stability [76]. Briefly, the CRISPR/Cas9 system works by inserting
a vector in target cells containing a guide RNA sequence and Cas9 DNA. When the
Cas9 protein its expressed it recognizes the guide RNA and the flanking palindromic
repeats of the target DNA to bind and make double strand breaks around the gene
of interest [76]. When the cell tries to repair these breaks it generates premature
stop codons, not allowing the process of translation to take place or translating an
aberrant non-functional form of the protein of interest. In addition, since this system
works at the genomic level, the changes are considered stable and permanent [76].
Since Her4 has been shown to play an important role in survival under
adverse culture conditions and stressors including anoikis and confers metastatic
capability in pediatric malignancies and we observed an increased expression of
Her4 in conditions used to enrich a stem-like population in OS (see Chapter 4), we
wanted to decipher the specific contributions of this receptor in a stem-like
phenotype in OS. In this chapter, we focused on exploring how different validated
OS markers used to identify cells with tumorigenic potential are affected after Her4
knockout.
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Results
Generation of Her4 CRISPR/Cas9 clones
Various guide RNA sequences to different regions of Her4 were designed and
inserted in the plasmid vector shown in Figure 10. The cell line CCHD was used to
generate full-length Her4 knockouts since it has a high endogenous expression of
this receptor. After transfection, GFP positive cells expressing the CRISPR vector
were sorted and single clones were plated, expanded and Her4 expression was
verified by western blot. Figure 11 and Figure 12 show verification of the
downregulation of Her4 expression in single clones selected by western blot and
flow cytometry for Her4. Using the CRISPR vector we were able to obtain high
knockout efficiency compared to previous attempts using shRNA to Her4 (data not
shown).

Figure 10: Cas9 expression vector used to generate Her4 knockouts.
Her4 knockouts were generated by transfection of expression vectors containing
various guide RNA sequences to full length Her4, the Cas9 protein and GFP to allow
selection of transfected cells.
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Figure 11: CRISPR constructs targeting Her4 show high knockout efficiency.
CRISPR/Cas9 vectors were transfected using lentivirus into CCHD. Parental cell line
with guide RNA not targeting any specific gene is labeled Nonsense control (NC).
Three different clones are depicted above (JMX-1-1, 1-3, and 1-4). Mcf7 is a breast
carcinoma cell line and Her4 positive control. 60ng of protein lysate were loaded.

Figure 12: Her4 knockout verification by flow cytometry corroborates effective
deletion. Using an antibody that specifically recognizes Her4 surface expression we
observed that this receptor was efficiently deleted at the genomic level. Black lines
show unstained negative control, blue is isotype and purple is Her4 APC expression
level.
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Surface expression of tumor initiating cell markers is not affected by Her4
knockout
Next, we wanted to determine whether Her4 knockout affected the expression
of validated surface markers for OS stem-like cells. For this, we used flow cytometry
and measured the level of stem-like markers CD117 and Stro1 together with Her4
expression in CRISPR clones 1-1 and 1-4 compared to nonsense control. Figure 13
shows that in monolayer culture the expression of these markers is so low that there
is not an obvious effect of genomic deletion of Her4. Therefore, we proceeded to
generate sarcospheres for both nonsense control and CRISPR clones in order to
determine whether changes in expression of these markers occur after sarcosphere
culture induces its expression, as has been previously demonstrated [29]. While
sarcospheres were formed by the CRISPR clones, upon dissociation of these
CRISPR spheres into single cells most of these cells are non-viable. We interpret
this to mean that Her4 expression is necessary for cells to be able to withstand
dissociation from spheres.
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Figure 13: Expression of OS stemness markers CD117 and Stro1 is not
affected in monolayer culture after Her4 knockout. Flow cytometry staining of
CCHD nonsense control and CCHD CRISPR clone 1-4 does not show significant
effect of Her4 knockout in stem cell marker expression since basal levels of these
markers are extremely low. Attempts to obtain single cell suspensions after
sarcosphere culture in Her4 knockout clones were unsuccessful due to low cell
viability.

Her4 knockout mitigates Aldehyde dehydrogenase activity
Aldehyde dehydrogenase (ALDH) activity has been studied extensively as a
marker for cancer cells with tumor initiating potential in many tumor types, including
OS [32, 77, 78]. It has also been validated as a marker for OS stem-like cells and it
confers tumor cells with an increased detoxifying capability making them more
resistant to chemotherapy and more tumorigenic [32]. We therefore analyzed the
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activity of this enzyme in our control and CRISPR clones by measuring the
percentage of Aldefluor bright cells after addition of the Aldefluor substrate. Figure
14 and Figure 15 demonstrate that the percentage of Aldefluor bright cells in the
CRISPR Her4 clones CCHD 1-1, 1-3 and 1-4 is significantly decreased compared
with the CCHD nonsense control cells. In addition, we also looked at the activity of
this enzyme after growth under sarcosphere conditions and observed that CCHD
nonsense control cells are able to slightly increase their Aldefluor bright population
whereas the Her4 CRISPR clone JMX 1-1 cannot (see Figure 16).

Figure 14: Aldehyde dehydrogenase activity is decreased after deletion of
Her4. Using Aldefluor fluorescence as a surrogate for aldehyde dehydrogenase
activity, we were able to observe that Her4 CRISPR knockouts had a diminished
percentage of cells with high activity of this enzyme after addition of a fluorescent
substrate, which can only be processed by isoforms of ALDH.
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Figure 15: Quantification of ALDH Bright cells in CCHD nonsense and Her4
CRISPR Clones presented in Figure 14.
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Figure 16: Aldehyde dehydrogenase in Her4 knockout remains diminished
after sarcosphere culture. CRISPR clone CCHD JMX 1-1 and nonsense control
were grown under sarcospheres, dissociated into single cells and added aldefluor
substrate to measure activity of this enzyme. Enzymatic activity in the Her4 knockout
remain decreased compared to the nonsense control.
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Expression of embryonic stem cell transcription factors is decreased in Her4
CRISPR clones even after sarcosphere culture

Sox2, Oct3/4 and Nanog are embryonic stem cell transcription factors
important in maintaining pluripotency and self-renewal in both normal tissue stem
cells and tumorigenic stem-like cells [31, 33]. These transcription factors were
initially observed in OS stem-like cells by Gibbs et al. who demonstrated that OS
sarcospheres upregulated expression of Oct4 and Nanog. To determine if the
expression of these transcription factors was affected after Her4 deletion, we
performed quantitative real-time PCR using validated hydrolysis probes. After growth
under sarcospheres the CRISPR clones were not able to upregulate the expression
of these factors when compared to the nonsense control (Figure 17).

Figure 17: Expression of pluripotency markers Sox2, Nanog and Oct4
decreases with Her4 genomic deletion. mRNA expression of Sox2, Nanog and
Oct4 was measured after seven days in sarcosphere culture for CCHD nonsense
control and CRISPR clones JMX 1-1, 1-3 and 1-4. Data was normalized to GAPDH
as internal control and compared relative to CCHD nonsense control. (*) denotes pvalue of less than 0.05.
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Summary
Validated markers for OS stem-like cells identify different subsets of cells
within a tumor with the ability to confer aggressive disease and to initiate tumors
even when implanted in very low numbers and these tumor cells can be serially
transplanted in mice each time recapitulating the heterogeneity of the initial tumor
[26]. Although no specific marker can accurately identify the entire pool of cells with
tumor initiating potential, it is thought that a combination of several markers can
provide a better understanding of this stem-like population [75, 79]. Through the
analysis of several markers for stem-like cells in OS, our data indicates that
aldehyde dehydrogenase activity and expression of embryonic stem cell
transcription factors are compromised following Her4 knockout. Therefore, this data
suggests that Her4 can modulate expression of markers associated with high
tumorigenic potential, thus validating our prognostic data (see Chapter 3) that
correlates Her4 with poor metastasis-free survival.
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Chapter 6: Overexpression of Her4 Jma isoforms in OS cell lines promotes
expression of stem-like markers
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Rationale
In the previous chapter, we observed how genomic deletion of Her4 in the
CCHD OS cell line mitigated the expression of markers that characterize cells with
stem-like activity. In this chapter, we wanted to explore how cells would be affected
after Her4 overexpression. Taking into consideration that the most common Her4
isoform found in OS cell lines is the juxtamembrane isoform Jma (see Chapter 3),
we wanted to observe whether there were specific effects mediated by the two Her4
cytoplasmic isoforms: Cyt1 and Cyt2. These two cytoplasmic isoforms differ by
mRNA splicing of exon 26 which encodes for a PI3K binding site and is expressed in
Cyt1 but not in Cyt2 [49, 50]. There have been various studies that have
demonstrated that these isoforms have complementary but distinct roles in the same
tissue, with Cyt2 mainly mediating proliferation and Cyt1mediating survival and
chemotaxis [51, 55, 80, 81]. Therefore, to uncover how Her4 is mediating its effects
in OS and to have an idea of the possible signaling pathways involved, we decided
to generate Her4 JmaCyt1 and JmaCyt2 overexpressing OS cell lines and measure
how the expression of embryonic stem cell transcription factors and OS stem-like
cell surface markers were affected.
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Results
Generation of Her4 JmaCyt1 and JmaCyt2 overexpressing cell lines.

To generate cell lines overexpressing the two different Her4 cytoplasmic
isoforms with the juxtamembrane isoform Jma, we used the vector shown in Figure
18 to transfect OS cell lines Maos and CCHM. These cell lines were chosen due to
their efficacy for transfection and their moderate level of Her4 expression among our
panel of patient derived OS cell lines. Selection of Her4 expressing cells was
performed by either GFP or puromycin selection.

Figure 18: Her4 JmaCyt1
and JmaCyt2 vector used
for transfection. OS cell lines
Maos and CCHM were
transfected using lentivirus
using the vector depicted.
Selection of transfected cells
was performed by either GFP
expression or puromycin
selection.
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Her4 JmaCyt1 isoform overexpression causes increased expression of
pluripotency markers Sox2, Nanog and Oct4.

Maos and CCHM OS cell lines containing either MigR1, Her4 JmaCyt1 or
Her4 JmaCyt2 were analyzed by quantitative real-time PCR for expression of
pluripotency markers Sox2, Nanog and Oct4 since we wanted to determine if by
overexpressing this receptor we were able to cause a shift towards a stem-like state
in these OS cells. Indeed, we observed that with the Her4 JmaCyt1 isoform there
was increased expression of these markers as shown in Figure 19. As a reminder,
published data with these transcription factors in OS demonstrated that growth
under sarcosphere conditions induced their expression and this correlated with
expression levels in vivo and with tumor initiation potential [26, 30].

52

Figure 19: Overexpression of the Her4 JmaCyt1 isoform upregulates
embryonic stem cell transcription factors. Real-time PCR was performed using
RNA extracted from OS cell lines Maos and CCHM with either MigR1 vector or
overexpressing Her4 JmaCyt1 or Her4 JmaCyt2. Her4 JmaCyt1 overexpressing
cells were able to upregulate expression of these markers in monolayer culture
without sarcosphere culture necessary for induction.
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Both Her4 JmaCyt1 and JmaCyt2 isoform overexpression in OS cell lines lead
to increased CD117 expression
Next, we wanted to investigate whether increasing Her4 expression in OS
affected expression of the surface markers Stro1 and CD117. Figure 20 shows that
there is low to moderate basal expression of CD117 in both OS cell lines Maos and
CCHM. In Maos MigR1 around 15% of the population expresses CD117 and 40% in
CCHM MigR1. When Her4 JmaCyt1 is overexpressed in Maos cells there is not an
evident increase in the total percentage of CD117 positive cells, however, 7% of the
population is now double positive for both Her4 and CD117 in the JmaCyt1 construct
compared with 0.1% in the control MigR1 cells. With Maos JmaCyt2, the total
percentage of CD117 positive cells increased from 15% to 23% with now around
20% of the population staining for Her4 and CD117 simultaneously. In CCHM, the
majority of the CD117 positive cells also stained for Her4 in the JmaCyt1 construct
and with the JmaCyt2 construct the total percentage of CD117 positive cells
increased from 40% to 64% with the majority staining for Her4 as well. Therefore,
these results indicate that overexpression of Her4 JmaCyt1 and JmaCyt2 in OS cells
results in increased numbers of Her4/CD117 double positive cells and an increase in
the total percentage of CD117 positive cells.
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Figure 20: Her4 positive cells co-localize with CD117 positive cells. Maos and
CCHM OS cell lines overexpressing Her4 JmaCyt1 or JmaCyt2 grown in monolayer
culture were stained for flow cytometry analysis with Her4 and CD117. Both cell
lines have basal expression of CD117 as seen in the MigR1 vector. However, when
Her4 is overexpressed the majority of the CD117 positive cells also express Her4.
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Summary
In this chapter, we have observed the direct effects of Her4 overexpression in
OS cell lines. As others have reported in other tumor types, we observed that the
two cytoplasmic isoforms of Her4 lead to distinct effects in vitro. In terms of
expression of embryonic stem cell transcription factors, increasing the levels of the
Her4 JmaCyt1 isoform, but not JmaCyt2 lead to increased levels of Sox2, Nanog
and Oct4. However, in terms of surface expression of the stemness marker CD117,
although Her4 JmaCyt1 seems to co-stain with CD117 positive cells, overexpression
of the Her4 JmaCyt2 isoform caused an increase in the total number of CD117
positive cells. Therefore, this data suggests that these two different isoforms might
mediate a stem-like phenotype in OS by different but converging signaling pathways.
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Chapter 7: Discussion and Future Directions
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Development of metastatic disease and distant tumor initiation is a complex
process that requires resilience and survival of cancer cells under adverse
environments on the route to metastasis [69, 70, 82-84]. This process requires that
cancer cells locally invade, intravasate and survive in circulation and arrest and
extravasate in the metastatic niche [85]. Research studies in hematologic and solid
malignancies have demonstrated that the majority of cancer cells within a tumor do
not possess this ability; therefore tumors are considered heterogeneous
conglomerates of malignant cells [26, 72]. Tumor cells with the innate ability to
initiate tumors and with higher metastatic potential have been identified in vitro and
in vivo by their ability to grow and travel as small clusters of cells and by using
markers and enzymatic abilities that are attributed to normal stem cells, hence they
have been termed cancer stem cells or stem-like cancer cells. The plasticity of this
phenotype has been demonstrated in melanoma [21, 77] and other tumors including
osteosarcoma [41], and regulators of this phenotype would allow for better
understanding of metastasis progression and to develop effective targetable
therapies that would benefit these patients.
Although relatively little is known about Her4 and its contribution in cancer
compared to other EGFR family members like Her2, recent reports have shown that
this receptor is highly expressed in malignancies like breast cancer, melanoma,
colon and lung cancer and its expression correlates with aggressive disease and
metastasis [57, 60, 61, 86-89]. In pediatric malignancies like Ewing sarcoma and
neuroblastoma, Her4 is necessary for anoikis resistance and survival under noxious
stimuli [56, 58, 59]. Her4 is overexpressed in OS patients in both primary tumors and
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metastatic lesions [65, 66], however the relevance of this receptor in OS has not
been previously described. Since Her4 expression seems to be an important factor
for survival in many malignancies mediating its effects by conferring resilience under
stressors and similar conditions are used to enrich cancer cells with a stem-like
phenotype, we sought to determine the importance of Her4 in OS and whether its
effects could be mediated by the promotion of a stem-like phenotype in OS.
In Chapter 3 we demonstrated that Her4 expression has prognostic
significance in OS patients, where high Her4 expression in their diagnostic biopsies
correlated with a diminished metastasis free survival. This finding has potential for
clinical translation in patients initially diagnosed with OS. Upon diagnosis, OS
patients undergo 2-3 cycles of induction with high-dose methotrexate, doxorubicin
and cisplatin (MAP) chemotherapy comprising a period of 10-12 weeks [9, 90].
Then, tumor response is evaluated by imaging and histologic analysis and patients
are stratified in good and poor responders based on the level of necrosis in their
tumors. This entails that patients have to wait at least three months to know if their
chemotherapy regime is adequate in order to treat their tumor. If Her4 indeed has
prognostic potential, upon OS diagnosis Her4 expression can be assessed and
patients that express Her4 in their tumors can be offered aggressive chemotherapy
initially since it is expected that these patients will have a higher probability of
developing metastatic disease. Further experiments to validate Her4 as a potential
prognostic marker need to show how Her4 expression is comparable to percent
necrosis after induction chemotherapy.
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Although these observations correlating Her4 expression to decreased
metastasis free survival may suggest a link between Her4 and formation of
metastasis, it is necessary to directly address whether Her4 expression is sufficient
to promote development of metastatic disease to the lungs in OS. For this, we can
design an in vivo experiment with CCHD OS cell line with and without Her4 and Fas
expression. Fas expression in OS has been demonstrated to be vital for
development of metastasis [91, 92], with primary OS tumors having variable Fas
expression but Fas negative OS cells are selected for metastatic growth. Taking
advantage of this, we can observe whether it will be possible to rescue metastatic
potential in Fas positive cells after Her4 overexpression. This experiment will then
establish Her4 as a sufficient mechanism to drive OS metastatic disease.
In Chapter 3 we also investigated the Her4 juxtamembrane expression level
in a panel of commercially available OS cell lines and patient-derived cell lines. In
this experiment we demonstrated that patient derived cell lines have comparable
Her4 expression to that of OS patient biopsies. Furthermore, published data on Her4
expression in OS suggests that this receptor is mainly localized in the cytoplasm of
tumor cells [65, 66], where it could be possibly mediating its effects. Our data from
patient-derived OS cell lines is consistent with these observations since we showed
that Jma is the highest expressing Her4 isoform in these cell lines. As discussed in
Chapter 1, only the juxtamembrane isoforms Jma and Jmd can undergo proteolytic
cleavage by ADAMS17 and gamma-secretase to release a soluble intracellular
fragment of the Her4 receptor [49]. Experiments to understand the impact of
expression of cleavable Her4 isoforms in OS should further analyze the level of
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expression of these cleavable isoforms in more patient derived cell lines and/or
patient tissue samples and if Jma or Jmd are validated as the most prevalent
isoforms, specific mutations on exon 16 (the ADAMS17 binding site) could be
generated and determine if there is any impact on in vivo tumor formation.
Alternatively, non-cleavable isoforms of Her4 (Jmb and Jmc) could be
overexpressed and similar experiments could be performed. Furthermore, to truly
understand the pathobiology of Her4 in OS, in vivo models using patient xenografts
should be performed, as they will more accurately represent actual disease and
Her4 expression in OS patients.
To understand whether Her4 expression was affected by conditions used to
enrich cells with a stem-like phenotype, in Chapter 4 we studied Her4 expression
with validated markers used to identify cells with tumor initiating potential in OS.
From this set of experiments we observed that Her4 expression is inducible after
sarcosphere culture and that expression of CD117 and Stro1, published markers for
OS stem-like cells [29], is mainly exhibited by Her4 expressing cells. Although
previous experiments have demonstrated that Her4 becomes upregulated under
anchorage independence [56, 58], our results are the first to directly study Her4
under conditions that are used to enrich cancer stem-like cells. Sarcosphere
conditions have important translational implications. Recent studies have uncovered
that the majority of tumor cells able to form metastatic disease travel to their niche
as small cellular clusters [70, 83, 84], and thus this culture system serves as a useful
in vitro model of tumor cell interaction. In addition, these findings support a possible
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targetable mechanism to identify cancer stem-like cells in OS, which are thought to
display increased metastatic potential [26, 30].
In Chapter 5 we assessed the specific contributions of Her4 to OS stem-like
populations by generating CRISPR/Cas9 constructs targeting this receptor and
causing genomic deletion. Our studies with Her4 knockout clones from the patient
derived OS cell line CCHD demonstrated that when Her4 expression is abrogated
there is decreased aldehyde dehydrogenase activity and decreased expression of
embryonic stem cell transcriptions factors Sox2, Nanog and Oct4. These markers
have been shown to identify highly tumorigenic subpopulations in OS [30] [28].
Therefore, this data further supports a possible role of Her4 as an upstream
mediator of a stem-like phenotype. Further experiments to corroborate these
observations are needed and should mainly focus on in vivo models. In vitro models,
although useful to test hypothesis in a cost-effective manner, have certain limitations
that become more evident when studying cells with stem-like attributes. As
discussed in Chapter 1, characterization of cells that have the ability to initiate
tumors should not focus only on a specific surface marker or enzymatic ability.
Rather, studying a collective array of abilities and molecules expressed in these cells
allow for better understanding and more accurate representation of this population.
Additionally, the gold standard to assess tumor-initiating capacity is self-renewal [22,
70, 75]. This refers to the ability that cancer stem-like cells have, like tissue stem
cells, to undergo asymmetric cellular division to generate both identical and more
differentiated progeny, thereby allowing single cancer cells to recapitulate tumor
heterogeneity. Using in vivo models can only accurately represent this ability. An
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ideal experiment to assess whether Her4 affects tumor-initiating capacity should be
performed by injecting Her4 high and low OS cells in low numbers (around 100 cells)
intratibially in mice. Since it is thought that even one cancer cell with stem-like
features can recapitulate its parental tumor with similar tumor heterogeneity [75], this
first experiment will allow us to see if by having Her4 expression the ability of OS
cells to initiate tumors is enhanced, even when OS cells are injected in low
concentration. Furthermore, to demonstrate self-renewal in mouse models, serial
transplantation should be performed by isolating OS cells from primary bone lesions
and sorting for Her4 high and low expressing OS cells. These cells should then be
injected intratibially in a second set of mice. If Her4 expressing cells have selfrenewal capacity and represent a subset of OS cells with tumor initiating potential,
they should be able to efficiently recapitulate tumor heterogeneity in secondary
tumors whereas Her4 low OS cells should not. Currently, initial in vivo experiments
are undergoing in our lab where we performed intratibial injection of CCHD
nonsense control and CCHD CRISPR clone JMX 1-1 OS cells in NOD/SCID mice in
order to understand the effects of Her4 knockout in terms of primary tumor size,
metastatic disease burden and expression of OS stem-like markers. Taking into
account our observations from in vitro experiments, we expect to see that the
CRISPR mice will develop decreased metastatic lesions compared to our nonsense
control group. Additionally, we expect to observe decreased expression of OS stemlike markers in these tumors.
To further demonstrate the importance of Her4 for a stem-like phenotype, we
overexpressed the isoforms JmaCyt1 and JmaCyt2 as depicted in Chapter 6. The
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Jma isoform was selected for overexpression due to its abundance across patient
derived OS cell lines as shown in Chapter 3. Upon overexpression of these two Her4
isoforms we observed that expression of embryonic stem cell transcription factors
Sox2, Nanog and Oct4 increased with Her4 JmaCyt1 overexpression. Previous
experiments with OS cell lines showed upregulation of these transcriptions factors
after sarcosphere culture [30, 36] and our observations indicate that overexpressing
Her4 is enough to cause these factors to be upregulated. Also, upon Her4 JmaCyt2
overexpression we observed that CD117 expression increased. These findings
suggest that when Her4 is highly expressed, OS cells acquire a more aggressive
phenotype, as these markers have been linked to metastasis in OS and other tumor
models [26, 28, 29]. Also, these observations validate that different Her4 isoforms
may mediate different cellular effects as observed in breast cancer [53]. Clear
understanding of the roles of the various Her4 isoforms in OS and signaling
pathways activated is necessary. Although the Her4 Cyt1 isoform containing a PI3K
binding site has been demonstrated to mediate survival effects compared to more
proliferative effects of Her4 Cyt2, the latter preferentially binds transcription
regulators and translocates to the nucleus to regulate transcription [49, 50, 93]. The
Yes-associated protein 1(YAP1) is one such transcription coactivator that selectively
binds Her4 Cyt2 in the nucleus, leading to transcription of a genetic signature to
promote migration [94, 95]. YAP1 in turn, has been associated with a cancer stem
cell phenotype on breast cancer [96-98]. Therefore, we predict that effects of the
cytoplasmic isoforms of Her4 in OS are specific but complementary to promote a
stem-like phenotype.
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In conclusion, the observations presented herein suggest that Her4 can be an
important mediator of aggressive disease in OS through the induction of a stem-like
phenotype. These findings are of great translational potential and can lead to the
development of new and targeted therapies in order to improve survival among OS
patients, which has remained unchanged for the past 20 years [1]. More so,
individualized chemotherapy regimens can be designed for OS patients who are at
risk for developing metastasis. Conversely, in those patients with low Her4 and a
better prognostic outcome the chemotherapy exposure may be able to be reduced in
terms of number of post-op cycles of chemotherapy agents that can diminish quality
of life and may lead to development of secondary malignancies during adulthood
years.
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